Amylin, Lilly Wrap Up Diabetes Drug Alliance, Lawsuit
Amylin Pharmaceuticals Inc. said Tuesday that it would pay Eli Lilly & Co. $250 million now and up to $1.2 billion later to end a lucrative diabetes drug joint marketing agreement...To view the full article, register now.
Already a subscriber? Click here to view full article